Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Status:
Terminated
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This multi-institutional phase I/II clinical trial will test the tolerability and efficacy of
the combination sorafenib and topotecan in patients with recurrent ovarian cancer, which is
platinum-resistant (recurrence within 6 months from completing platinum based therapy) or
refractory (progressive disease during platinum based therapy).